The importance of the eicosanoid pathway in lung cancer

Lung Cancer

Volumn 41, Issue SUPPL. 1, 2003, Pages 73-79

  Laskin, Janessa J ^a   Sandler, Alan B ^a  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

COX 2; Eicosanoids; Lung cancer; Toxic drugs

Indexed keywords

CARBOPLATIN; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; ICOSANOID; NONSTEROID ANTIINFLAMMATORY AGENT; PACLITAXEL; PHENIDONE;

CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFECT; DRUG TOLERABILITY; DRUG TOXICITY; ENZYME ACTIVITY; HISTOPATHOLOGY; HUMAN; LUNG CARCINOMA; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 0038350456     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(03)00145-4     Document Type: Conference Paper

References (34)

1. Jemal A., Thomas A., Murray T., Thun M. Cancer statistics, 2002. Ca: A Cancer Journal for Clinicians. 52:2002;23-47.
2. Smalley W., Ray W.A., Daugherty J., Griffin M.R. Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer: a population-based study. Archives of Internal Medicine. 159:1999;161-166.
3. Thun M.J., Namboodiri M.M., Heath C.W. Jr. Aspirin use and reduced risk of fatal colon cancer. New England Journal of Medicine. 325:1991;1593-1596. [comment].
4. Waddell W.R., Loughry R.W. Sulindac for polyposis of the colon. Journal of Surgical Oncology. 24:1983;83-87.
5. Masferrer J.L., Leahy K.M., Koki A.T., Zweifel B.S., Settle S.L., Woerner B.M., Edwards D.A., Flickinger A.G., Moore R.J., Seibert K. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Research. 60:2000;1306-1311.
6. Gupta R.A., Dubois R.N. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2, Nature Reviews. Cancer. 1:2001;11-21.
7. Tsujii M., Kawano S., DuBois R.N. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proceedings of the National Academy of Sciences of the United States of America. 94:1997;3336-3340.
8. Williams C.S., Smalley W., DuBois R.N. Aspirin use and potential mechanisms for colorectal cancer prevention. Journal of Clinical Investigation. 100:1997;1325-1329.
9. Giovannucci E., Egan K.M., Hunter D.J., Stampfer M.J., Colditz G.A., Willett W.C., Speizer F.E. Aspirin and the risk of colorectal cancer in women. New England Journal of Medicine. 333:1995;609-614. [comment].
10. Giovannucci E., Rimm E.B., Stampfer M.J., Colditz G.A., Ascherio A., Willett W.C. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Annals of Internal Medicine. 121:1994;241-246. [see comments].
11. Giardiello F.M., Hamilton S.R., Krush A.J., Piantadosi S., Hylind L.M., Celano P., Booker S.V., Robinson C.R., Offerhaus G.J. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. New England Journal of Medicine. 328:1993;1313-1316.
12. Tsujii M., Kawano S., Tsuji S., Sawaoka H., Hori M., DuBois R.N. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 93:1998;705-716. [published erratum appears in Cell July 24;94(2):following 271].
13. Seed M.P., Brown J.R., Freemantle C.N., Papworth J.L., Colville-Nash P.R., Willis D., Somerville K.W., Asculai S., Willoughby D.A. The inhibition of colon-26 adenocarcinoma development and angiogenesis by topical diclofenac in 2.5% hyaluronan. Cancer Research. 57:1997;1625-1629.
14. Hida T., Kozaki K., Muramatsu H., Masuda A., Shimizu S., Mitsudomi T., Sugiura T., Ogawa M., Takahashi T. Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clinical Cancer Research. 6:2000;2006-2011.
15. Wolff H., Saukkonen K., Anttila S., Karjalainen A., Vainio H., Ristimaki A. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Research. 58:1998;4997-5001.
16. Hida T., Yatabe Y., Achiwa H., Muramatsu H., Kozaki K., Nakamura S., Ogawa M., Mitsudomi T., Sugiura T., Takahashi T. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Research. 58:1998;3761-3764.
17. Hosomi Y., Yokose T., Hirose Y., Nakajima R., Nagai K., Nishiwaki Y., Ochiai A. Increased cyclooxygenase 2 (COX-2) expression occurs frequently in precursor lesions of human adenocarcinoma of the lung. Lung Cancer. 30:2000;73-81.
18. Achiwa H., Yatabe Y., Hida T., Kuroishi T., Kozaki K., Nakamura S., Ogawa M., Sugiura T., Mitsudomi T., Takahashi T. Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clinical Cancer Research. 5:1999;1001-1005.
19. Khuri F.R., Wu H., Lee J.J., Kemp B.L., Lotan R., Lippman S.M., Feng L., Hong W.K., Xu X.C. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clinical Cancer Research. 7:2001;861-867.
20. Hida T., Leyton J., Makheja A.N., Ben-Av P., Hla T., Martinez A., Mulshine J., Malkani S., Chung P., Moody T.W. Non-small cell lung cancer cycloxygenase activity and proliferation are inhibited by non-steroidal antiinflammatory drugs. Anticancer Research. 18:1998;775-782.
21. Rioux N., Castonguay A. Inhibitors of lipoxygenase: a new class of cancer chemopreventive agents. Carcinogenesis. 19:1998;1393-1400.
22. Kwong M., Holmes G., Jiao X., Zeng Q., Krasna M.J., Edelman M.J. Cyclooxygenase-2 (COX-2) inhibition of cellular proliferation in non-samll cell lung cacner is enhanced by co-administration with 5-lipoxygenase (5-LOX) inhibitor. ASCO Molecular Therapeutics Symposium, San Diego. 2002.
23. Teicher B.A., Korbut T.T., Menon K., Holden S.A., Ara G. Cyclooxygenase and lipoxygenase inhibitors as modulators of cancer therapies. Cancer Chemotherapy & Pharmacology. 33:1994;515-522.
24. Soriano A.F., Helfrich B., Chan D.C., Heasley L.E., Bunn P.A. Jr., Chou T.C. Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines. Cancer Research. 59:1999;6178-6184.
25. Hida T., Kozaki K., Ito H., Miyaishi O., Tatematsu Y., Suzuki T., Matsuo K., Sugiura T., Ogawa M., Takahashi T. Significant growth inhibition of human lung cancer cells both in vitro and in vivo by the combined use of a selective cyclooxygenase 2 inhibitor, JTE-522, and conventional anticancer agents. Clinical Cancer Research. 8:2002;2443-2447.
26. Milas L., Kishi K., Hunter N., Mason K., Masferrer J.L., Tofilon P.J. Enhancement of tumor response to gamma-radiation by an inhibitor of cyclooxygenase-2 enzyme. Journal of the National Cancer Institute. 91:1999;1501-1504. [comment].
27. Kishi K., Petersen S., Petersen C., Hunter N., Mason K., Masferrer J.L., Tofilon P.J., Milas L. Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor. Cancer Research. 60:2000;1326-1331.
28. Petersen C., Petersen S., Milas L., Lang F.F., Tofilon P.J. Enhancement of intrinsic tumor cell radiosensitivity induced by a selective cyclooxygenase-2 inhibitor. Clinical Cancer Research. 6:2000;2513-2520.
29. Pyo H., Choy H., Amorino G.P., Kim J.S., Cao Q., Hercules S.K., DuBois R.N. A selective cyclooxygenase-2 inhibitor, NS-398, enhances the effect of radiation in vitro and in vivo preferentially on the cells that express cyclooxygenase-2. Clinical Cancer Research. 7:2001;2998-3005.
30. Altorki N.K., Keresztes R.S., Port J.L., Flieder D.B., Ferrara C.A., Pasmantier M.W., Libby D.M., Yankelevitz D., Dannenberg A.J. Celecoxib (Celebrex), a selective COC-2 inhibitor, enhances the response to preoperative paclitaxel/carboplatin in early stage non-small cell lung cancer. American Society of Clinical Oncology. 2002.
31. Csiki I., Dang T., Sandler A.B., Carbone D., Choy H., Campbell N., Garcia B., Morrow J., Johnson D.H. Cyclooxygenase-2 (COX-2) inhibition + docetaxel in recurrent non-small cell cancer (NSCLC): preliminary results of a phase II trial (THO-054). American Society of Clinical Oncology. 2002.
32. Carbone D., Choy H., Csiki I., Dang T., Campbell N., Garcia B., Morrow J., Saha D., Johnson D.H., Sandier A.B. Serum/plasma VEGF level changes with cyclooxygenase-2 (COX-2) inhibition in combined modality therapy in stage III non-small cell lung cancer (NSCLC): preliminary results of a phase II trial (THO-0059). American Society of Clinical Oncology. 2002.
33. Waskewich C., Blumenthal R.D., Li H., Stein R., Goldenberg D.M., Burton J. Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines. Cancer Research. 62:2002;2029-2033.
34. Heasley L.E., Thaler S., Nicks M., Price B., Skorecki K., Nemenoff R.A. Induction of cytosolic phospholipase A2 by oncogenic Ras in human non-small cell lung cancer. Journal of Biological Chemistry. 272:1997;14501-14504.